NCT02998398View on ClinicalTrials.gov

Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital

CompletedOBSERVATIONAL
Enrollment

262

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 29, 2016

Conditions
Rheumatoid ArthritisSpondyloarthritisCrohn's DiseaseUveitis
Interventions
OTHER

Switch from REMICADE® to INFLECTRA®

Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months

Trial Locations (1)

75014

Hôpital Cochin, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02998398 - Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital | Biotech Hunter | Biotech Hunter